Gilead Made Gains In Oncology, Though Virology Remains King
New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021
Executive Summary
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
You may also be interested in...
Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.